Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01452464 · ClinicalTrials.gov registry record
Safety of MenACWY-CRM Vaccination in Adolescents
A clinical trial, sponsored by Novartis Vaccines.
- Completed
- Registry status
- 55,397
- Enrollment target
NCT01452464: Completed study, sponsored by Novartis Vaccines.
NCT01452464 is a clinical trial that has completed, run by Novartis Vaccines. The registered enrollment target is 55,397 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01452464 has completed, sponsored by Novartis Vaccines.
- COMPLETED
- Registry status
- 55,397 participants
- Enrollment target
Study Summary
The purpose of this US FDA post-marketing commitment study is to evaluate the safety of MenACWY-CRM among 50.000 vaccinated adolescents within a large US Healthcare Maintenance Organization who received MenACWY-CRM vaccination as part of their routine clinical care. The pre-specified 26 events of interest are events commonly evaluated in vaccine safety studies and include certain neurological, immunological, vascular, musculoskeletal and hematologic disorders. All events are collected retrospectively.
Interventions
- BIOLOGICAL MenACWY-CRM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55,397 participants |
| Start Date | 2011-09 |
| Est. Completion | 2015-02 |
What the finished NCT01452464 record still lists
NCT01452464 is an observational study that tracks outcomes without assigning an intervention. Its 55,397 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which MenACWY-CRM is the first listed.
NCT01452464 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01452464 about?
NCT01452464 is a clinical study titled "Safety of MenACWY-CRM Vaccination in Adolescents". The purpose of this US FDA post-marketing commitment study is to evaluate the safety of MenACWY-CRM among 50.000 vaccinated adolescents within a large US Healthcare Maintenance Organization who received MenACWY-CRM vaccination as part of their routine clinical care. The pre-specified 26 events of in...
What is the current status of trial NCT01452464?
This trial is currently completed. The enrollment target is 55,397 participants. The study started on 2011-09. Estimated completion is 2015-02.
What interventions are being tested in trial NCT01452464?
The interventions under investigation include: MenACWY-CRM (BIOLOGICAL).
Who is sponsoring clinical trial NCT01452464?
This trial is sponsored by Novartis Vaccines, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07224243 · 54,000 participants · NA
Impact of Intraoperative Oxygenation Practices on Patient Outcomes
- NCT05975671 · 52,500 participants · NA
Reducing Empiric VAncomycin Use in Pediatric Suspected Sepsis
- NCT06355934 · 52,121 participants
OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
- NCT00785525 · 60,000 participants · Phase 3
Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia